Novartis AG (NVS)
| Market Cap | 268.82B +13.0% |
| Revenue (ttm) | 56.69B +2.7% |
| Net Income | 12.76B -6.6% |
| EPS | 6.61 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 21.07 |
| Forward PE | 15.21 |
| Dividend | $3.08 (2.19%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 1,554,268 |
| Open | 141.96 |
| Previous Close | 140.37 |
| Day's Range | 140.96 - 142.18 |
| 52-Week Range | 121.57 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 156.56 (+11.05%) |
| Earnings Date | Oct 27, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $156.56, which is an increase of 11.05% from the latest price.
News
Novartis' Pipeline In Focus After A Series Of Clinical Setbacks
(RTTNews) - Novartis has come under increasing pressure after a series of clinical and pipeline setbacks in the second half of 2026, culminating in calls from a major shareholder for changes to the co...
Novartis announces positive CHMP opinion for Cosentyx
Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Cosentyx in po...
Novartis Halts Development Of VHB937 After ASTRALS Phase 2 Trial Fails To Meet Endpoint
(RTTNews) - Novartis (NVS) announced on August 25, 2026, that its ASTRALS Phase 2 clinical trial evaluating VHB937 for amyotrophic lateral sclerosis did not meet its primary or secondary endpoints, le...
Novartis halts ALS drug development after mid-stage trial failure
Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest disappointment for the Swiss drugmake...
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy ...
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
CBSE Primary Teachers Tier 2 Result Out For KVS, NVS: Check Next Steps
CBSE Teacher Recruitment: Candidates are advised to regularly visit the official websites of CBSE, KVS and NVS and their application login for further updates.
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developing a therapy for lowering Lp(a).
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Novartis: More Pain on the Way?
The bad diagnoses just keep on coming for the Swiss drugmaker.
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Novartis investors to increase scrutiny of company’s strategy, Reuters reports
Novartis (NVS) investors will be increasing their scrutiny of the company’s dealmaking strategy following setbacks to drugs acquired through mergers and acquisitions, Bhanvi Satija, Oliver Hirt and Ma...
Focus: Novartis investors turn spotlight on M&A after trial setbacks
Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its...
Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
Major Novartis shareholder calls for board shake-up after drug trial setbacks: Reuters exclusive
A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker’s board to improve corporate governance after several trial setbacks.
Novartis shareholder calls for board changes, Reuters reports
A major Novartis (NVS) shareholder is calling for board changes following successive clinical setbacks and concerns over the company’s acquisition track record, arguing that stronger deal oversight an...
Stocks making the biggest moves premarket: Macy's, Meta, Apple, Novartis and more
These are the stocks posting the largest moves in the premarket.
Major Novartis shareholder calls for board shake-up after drug trial setbacks
A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered a record fall this week following back-to-back trial...
HSBC upgrades Novartis to Hold with negative catalysts played out
HSBC last night upgraded Novartis (NVS) to Hold from Reduce with a price target of $136, up from $123. The firm believes the company’s negative catalyst path has played out…
Novartis upgraded to Hold from Reduce at HSBC
HSBC upgraded Novartis (NVS) to Hold from Reduce with a CHF 110 price target
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
Novartis shareholders awoke to a more than 12.5% decline at open on September 8, 2026, after the Company reported that its Phase 3 HARBOR study of del-desiran and Phase 3 HORIZON study of pelacarsen d...
Anthropic has the right mindset when it comes to AI safety, says board Member Vas Narasimhan
Vas Narasimhan, CEO at Novartis and board member of Anthropic, joins 'Squawk on the Street' to respond to the recent statements of former researcher who warns that AI may soon prove to be a threat to ...
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss disappointing drug trial results soon after acquiring Avidity, the response to investors and more.